Quarterly ResultMay 29, 2026, 07:21 AM
CollPlant Q1 Revenue $73K, Net Loss $3.1M; Explores Strategic Alternatives
AI Summary
CollPlant Biotechnologies reported a significant decline in Q1 2026 GAAP revenues to $73,000 from $2.1 million in Q1 2025, primarily due to a non-recurring milestone payment last year, resulting in a net loss of $3.1 million, up from $1.5 million. The company is actively engaged in discussions for potential collaborations in medical aesthetics and advancing its next-generation dermal filler platform, securing a patent in Korea. Additionally, CollPlant has initiated a process to evaluate strategic alternatives to maximize shareholder value, alongside implementing cost-cutting measures including a 50% headcount reduction.
Key Highlights
- Q1 2026 GAAP revenues decreased to $73,000 from $2.1 million in Q1 2025.
- Q1 2026 GAAP net loss increased to $3.1 million ($0.23/share) from $1.5 million ($0.13/share) in Q1 2025.
- Cash and cash equivalents stood at $4.3 million as of March 31, 2026.
- Initiated evaluation of strategic alternatives to maximize shareholder value.
- Engaged in discussions for potential collaborations in medical aesthetics.
- Granted a patent in Korea for photocurable dermal filler technology.
- Launched BioFlex, an rhCollagen-based kit for 3D bioprinting applications.
- Implemented cost reduction plan, including a ~50% headcount reduction.
Price Impact
More from CLGN